Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Supports NUS-Led Research Consortium to Identify, Map Lipid Levels in Healthy People

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
New international effort to develop world's first integrated systems biology database for different races and ethnicities.

Agilent Technologies announced its support for a new international research consortium, led by the National University of Singapore (NUS), that aims to develop the world's first lipid1 database for healthy persons of different racial and ethnic groups.

Using the lipid database, scientists and researchers hope to better understand the healthy and unhealthy "fat" levels in people of different racial and ethnic backgrounds. This knowledge will pave the way for medical professionals to leverage such key information as diagnostic markers for their patients in future.

The Lipidomic Natural Variation (L-NAVA) consortium is founded by the Singapore Lipidomics Incubator (SLING) at NUS. Other founding members include South Korea's Graduate School of Analytical Science and Technology (GRAST) at Chungnam National University; Baker IDI Heart and Diabetes Institute, a medical research institute located in Melbourne, Australia; and Agilent, which is L-NAVA's preferred technology partner.

Using methodology created by SLING, the teams at GRAST and Baker IDI will undertake similar studies in their domestic markets; the results will be compiled into a database. (SLING recently concluded a study of 360 healthy subjects from three major ethnic groups-Chinese, Indian and Malay-in Singapore. Through that study, SLING was able to identify the upper and lower limits of the normal fat levels for healthy people in the three groups.)

The lipid information (L-NAVA) will be integrated with glycomic (G-NAVA) and proteomic (P-NAVA) studies, to provide insight into natural variation within glycans and proteins as well.

"Understanding natural variations is a major aim of SLING," said associate professor Markus Wenk, director of SLING. "This network allows us to extend, and hopefully connect, our studies on lipids with others that address variability at the level of genes, proteins and sugars. Doing this in healthy individuals will provide a broad, foundational basis relevant for a better understanding of onset of diseases." Dr. Wenk is also a faculty member at the Department of Biochemistry at the Yong Loo Lin School of Medicine at NUS and the Department of Biological Sciences at the NUS Faculty of Science.

"We are honored to be part of this new consortium, supporting its goal to systematically determine lipid profiles across different groups of humans," said Agilent's Rod Minett, general manager, Life Sciences, South Korea and the South Asia-Pacific region. "Agilent's innovations in bio-analytical instruments will help consortium members in their research on the natural variations using different methods. We hope this resource will help medical professionals provide better-quality care to their patients."

Principal investigators in the L-NAVA consortium are professor Wenk; professor Hyun Joo An, head of department at GRAST; associate professor Peter Meikle, head of Metabolomics at Baker IDI; and Dr. Rudolf Grimm, Agilent's director of Science and Technology and manager of collaborations in the Asia-Pacific region.

"Lipidomics has the potential to deliver significant new advances in medicine," said Professor Meikle. "These include being able to predict a person's risk of disease, understanding what causes that disease and being able to monitor and adjust treatments more effectively. However, to achieve these advances we must first understand the natural variation within different ethnic groups. We can then identify more accurately where abnormal lipid metabolism may be contributing to diseases including heart disease and diabetes."

"We are happy to be a founding member of this international consortium for lipidomics research," said professor An. "Although we have been focusing on the natural variation on serum glycoproteins to predict disease, we believe that the variation of glycans on lipid molecules can play a critical role in helping the scientific community gain deeper insights into the biological aspects of life. Our team at Asia Glycomics Reference Site is keen and ready to expand our research to lipidoglycomics, as glycolipids are closely involved in the development of neurons and their aging. This is a diversified yet interesting field that will benefit the global scientific and even medical communities."

All members of the consortium use Agilent's industry-leading triple quadrupole LC/MS system with ion funnel (iFunnel) technology in their lipidomics research. The Agilent iFunnel technology offers scientists and researchers the highest sensitivity and detection levels in their quest for scientific breakthroughs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with National University of Singapore
Company to support NUS Medicine's research for safer, more effective medicine for heart disease.
Friday, April 24, 2015
Scientific News
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
Ginger Nanoparticles Heal Bowel Disease
Lab team spins ginger into nanoparticles to heal inflammatory bowel disease.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
Exosome Research and Quality Control Using ZetaView
Particle Matrix's ZetaView particle characterisation system used by Cell Guidance Systems for exosome research.
Natural Metabolite Can Suppress Inflammation
An international group of scientists from US, Canada, Germany and Russia has revealed a substance produced in humans that can suppress the pro-inflammatory activity of macrophages – specific cells of immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!